Perfil
David O'Reilly worked as the Director of Corporate Development at ARIAD Pharmaceuticals, Inc. He then worked as the Chief Platform Officer at Proteus Digital Health, Inc. from 2014 to 2020.
Prior to that, he was the President of Catalyst Bioscience, Inc. and the Chief Business Officer of Iconix Biosciences, Inc. Mr. O'Reilly holds an MBA from Harvard University and an undergraduate degree from Wesleyan University.
Antiguos cargos conocidos de David O'Reilly.
Empresas | Cargo | Fin |
---|---|---|
Proteus Digital Health, Inc.
Proteus Digital Health, Inc. Pharmaceuticals: MajorHealth Technology Proteus Digital Health, Inc. develops medicine products and therapeutic devices. It provides digital health products that collect behavioral, physiologic, and therapeutic metrics, such as medication adherence, heart rate, sleep patterns, physical activity, and stress levels into personal management tools delivered to the mobile devices of consumers. The company was founded by Andrew M. Thompson, George M. Savage, and Mark J. Zdeblick in 2001 and is headquartered in Redwood City, CA. | Corporate Officer/Principal | 01/01/2020 |
ARIAD PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Iconix Biosciences, Inc.
Iconix Biosciences, Inc. BiotechnologyHealth Technology Iconix Biosciences is a multi-disciplinary company that integrates the skills and knowledge necessary for the creation of the world's largest toxicogenomics database of microarray and pharmacology data (DrugMatrix) with the informatics expertise and computer skills required to mine and interpret this vast body of information. Based on the data in DrugMatrix, Iconix has developed a library of Drug Signatures, genomic biomarkers that are predictive of specific toxicological endpoints and mechanisms of action. DrugMatrix and Drug Signatures provide a uniform source of molecular toxicology information, analytical tools, data mining algorithms and biomarkers to optimize drug candidates and predict their potential efficacy and toxicity before they advance to expensive preclinical and clinical development studies. Iconix's platform includes an integrated database architecture (IXIS) to bridge genomics and drug design, novel bio and chemoinformatics software, and advanced expression array and cellular expression assay development capabilities. This technology platform is coupled with an unparalled group of molecular toxicologists and bioinformaticians with years of experience in applying the tools and contextual data to provide clients with answers to critical scientific questions. Iconix has focused these capabilities on a line of products, licenses, services, and long-term collaborations. Iconix provides reports on customer compounds to classify them and help prioritize and select the best leads for advancement at all stages of discovery. Iconix has also entered exclusive alliances with collaborators to apply toxicogenomics data and know-how to customized drug discovery and development projects. Founded in 1998 by distinguished scientists and pharmaceutical industry professionals, Iconix has won the backing of some of the highest profile venture capitalists in the biotechnology and information technology industries. Iconix has also established alliances with leading global technology companies for the development and commercialization of its products, including MDS Pharma Services, Spotfire, Amersham Biosciences, MDL Information Systems, and Affymetrix. | Corporate Officer/Principal | - |
Catalyst Bioscience, Inc. /Old/
Catalyst Bioscience, Inc. /Old/ Medical SpecialtiesHealth Technology Catalyst Bioscience, Inc. develops and markets catalytic biopharmaceutical products. Its technology consists of methods to identify proteases with tailor-made specificity or improved pharmacological properties. The company was founded by Charles Craik, Sandra Waugh Ruggles and Christopher Thanos in 2003 and is headquartered in South San Francisco, CA. | President | - |
Formación de David O'Reilly.
Harvard University | Masters Business Admin |
Wesleyan University | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas privadas | 4 |
---|---|
ARIAD Pharmaceuticals, Inc.
ARIAD Pharmaceuticals, Inc. BiotechnologyHealth Technology ARIAD Pharmaceuticals, Inc. operates as an oncology company, which engages in the discovery, development, and commercialization of small-molecule drugs for the treatment of cancer. The company was founded by Harvey J. Berger and James E. Rothman on January 8, 1992 and is headquartered in Cambridge, MA. | Health Technology |
Proteus Digital Health, Inc.
Proteus Digital Health, Inc. Pharmaceuticals: MajorHealth Technology Proteus Digital Health, Inc. develops medicine products and therapeutic devices. It provides digital health products that collect behavioral, physiologic, and therapeutic metrics, such as medication adherence, heart rate, sleep patterns, physical activity, and stress levels into personal management tools delivered to the mobile devices of consumers. The company was founded by Andrew M. Thompson, George M. Savage, and Mark J. Zdeblick in 2001 and is headquartered in Redwood City, CA. | Health Technology |
Catalyst Bioscience, Inc. /Old/
Catalyst Bioscience, Inc. /Old/ Medical SpecialtiesHealth Technology Catalyst Bioscience, Inc. develops and markets catalytic biopharmaceutical products. Its technology consists of methods to identify proteases with tailor-made specificity or improved pharmacological properties. The company was founded by Charles Craik, Sandra Waugh Ruggles and Christopher Thanos in 2003 and is headquartered in South San Francisco, CA. | Health Technology |
Iconix Biosciences, Inc.
Iconix Biosciences, Inc. BiotechnologyHealth Technology Iconix Biosciences is a multi-disciplinary company that integrates the skills and knowledge necessary for the creation of the world's largest toxicogenomics database of microarray and pharmacology data (DrugMatrix) with the informatics expertise and computer skills required to mine and interpret this vast body of information. Based on the data in DrugMatrix, Iconix has developed a library of Drug Signatures, genomic biomarkers that are predictive of specific toxicological endpoints and mechanisms of action. DrugMatrix and Drug Signatures provide a uniform source of molecular toxicology information, analytical tools, data mining algorithms and biomarkers to optimize drug candidates and predict their potential efficacy and toxicity before they advance to expensive preclinical and clinical development studies. Iconix's platform includes an integrated database architecture (IXIS) to bridge genomics and drug design, novel bio and chemoinformatics software, and advanced expression array and cellular expression assay development capabilities. This technology platform is coupled with an unparalled group of molecular toxicologists and bioinformaticians with years of experience in applying the tools and contextual data to provide clients with answers to critical scientific questions. Iconix has focused these capabilities on a line of products, licenses, services, and long-term collaborations. Iconix provides reports on customer compounds to classify them and help prioritize and select the best leads for advancement at all stages of discovery. Iconix has also entered exclusive alliances with collaborators to apply toxicogenomics data and know-how to customized drug discovery and development projects. Founded in 1998 by distinguished scientists and pharmaceutical industry professionals, Iconix has won the backing of some of the highest profile venture capitalists in the biotechnology and information technology industries. Iconix has also established alliances with leading global technology companies for the development and commercialization of its products, including MDS Pharma Services, Spotfire, Amersham Biosciences, MDL Information Systems, and Affymetrix. | Health Technology |
- Bolsa de valores
- Insiders
- David O'Reilly